Femasys, Inc. (FEMY)

Over the past six months, Femasys, Inc.'s stock price has declined by approximately 42.43%. Key events include a Nasdaq extension to regain compliance with the minimum bid price requirement, a new distribution partnership in Switzerland, a partnership with Refuah Health Center to expand access to FemaSeed, FDA clearance for the next-generation FemVue diagnostic device, European approval for FemBloc, an $8.0 million underwritten public offering, and price declines following earnings reports.

Information explicitly detailing the demand seasonality for Femasys, Inc.'s products and services was not found in the provided search results.

Femasys, Inc. is a biomedical company focused on developing minimally invasive and non-surgical solutions for women's healthcare. Their product portfolio includes FemaSeed for infertility treatment, FemVue for fallopian tube assessment, FemCerv for cervical cancer diagnosis, FemCath for fallopian tube evaluation, FemChec for fallopian tube diagnosis, and FemBloc, a non-surgical permanent birth control solution under development.

Femasys, Inc. operates in the United States and internationally. The company is expanding its global presence with distribution partnerships in Switzerland and regulatory approvals in Australia and New Zealand for FemaSeed and FemVue. FemBloc has international approvals in Europe and the UK, with commercialization efforts expanding in European markets like France and the Benelux region.

Femasys, Inc. positions itself as a company focused on innovation and transformative healthcare for women, emphasizing safety. The company is recognized for addressing underserved areas in women's health through minimally invasive technologies. The brand has generally maintained a positive reputation among analysts, with a consensus rating of "Strong Buy" or "Moderate Buy". However, the company's survival depends on its ability to raise capital, the risk of Nasdaq delisting, and the potential risks related to the efficacy of its clinical programs.

Femasys, Inc. has a mix of institutional and individual owners. Institutional investors hold approximately 6.42% of the stock, insiders own about 4.05%, and retail investors hold the majority at 89.53%. Major institutional owners include Dauntless Investment Group, LLC, Vanguard Group Inc, Geode Capital Management, LLC, BlackRock, Inc., UBS Group AG, Northern Trust Corp, and State Street Corp. Notable individual insiders include Edward R. Uzialko, Kathy Leesepsick, John Dyett, John Q. Adams Jr., and Daniel Scott Currie.